10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancer

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) announced a multi-year research collaboration with Cleveland Clinic to advance diagnostic applications for bladder cancer. The partners will use 10x's Flex Apex, Xenium and later Atera platforms to study advanced bladder cancer tumor samples.

The project aims to identify clinically relevant biomarkers predicting response to antibody-drug conjugates and immunotherapies by integrating single cell transcriptomics, spatial gene expression and protein measurements with clinical outcomes.

News Market Reaction – TXG

+1.20%

42 alerts

+1.20% Session close to close

+7.4% Peak in 27 hr 49 min

$4.52B Market Cap

0.5x Rel. Volume

In the Jun 17 session, TXG gained 1.20%, reflecting a mild positive market reaction. Argus tracked a peak move of +7.4% during that session. Our momentum scanner triggered 42 alerts that day, indicating elevated trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a multi-year collaboration between 10x Genomics and Cleveland Clinic to...

Analysis

This announcement highlights a multi-year collaboration between 10x Genomics and Cleveland Clinic to apply single cell and spatial technologies in advanced bladder cancer, initially using Flex Apex and Xenium with plans to extend to Atera. The work targets clinically relevant biomarkers and links multimodal datasets to outcomes. In context of prior Atera and acquisition news, investors may monitor evidence generated from this program, its applicability across tumor types, and how it supports future diagnostic offerings.

Historical Context

5 past events · Latest: Jun 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 09	Strategic acquisition	Positive	+4.7%	Acquisition of Proteintech Genomics to expand single cell proteomics.
May 07	Earnings release	Neutral	-3.7%	Q1 2026 results with modest revenue decline and reaffirmed guidance.
Apr 29	Conference participation	Neutral	+9.2%	Announcement of participation in BofA Securities healthcare conference.
Apr 18	Product launch	Positive	-5.7%	Introduction of Atera spatial biology platform and related services.
Apr 15	Earnings date set	Neutral	-0.4%	Scheduled date and webcast details for upcoming Q1 2026 results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

News flow has produced mixed reactions: an acquisition and conference appearance saw strong gains, while a major product launch drew a notable selloff, indicating investors can react unpredictably to positive strategic updates.

Recent Company History

Over recent months, 10x Genomics has reported several strategic and corporate milestones. An acquisition of Proteintech Genomics on Jun 9, 2026 to expand proteomics capabilities coincided with a +4.73% move. Q1 2026 results on May 7, 2026 showed revenue of $150.8M and led to a -3.66% reaction. A BofA healthcare conference appearance on Apr 29, 2026 preceded a +9.16% gain, while the Atera platform launch on Apr 18, 2026 was followed by a -5.71% decline, underscoring uneven responses to innovation news.

Key Terms

antibody-drug conjugate, single cell, spatial platforms, biomarkers, +4 more

8 terms

antibody-drug conjugate medical

"aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response"

An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.

single cell medical

"using 10x's single cell and spatial platforms"

Single cell refers to the study or use of an individual cell rather than averaging measurements across many cells. Like listening to a single voice in a crowded room, single-cell approaches reveal differences and rare cell types that bulk measurements hide. For investors, single-cell data can de-risk drug development and diagnostics by pinpointing precise targets, explaining why a therapy works or fails, and enabling more tailored products that may command premium pricing or faster regulatory paths.

spatial platforms technical

"using 10x's single cell and spatial platforms"

Spatial platforms are software and hardware systems that let people and computers place, view and interact with digital content in three-dimensional physical or virtual space—think of apps and devices that layer virtual objects into a real room or create navigable 3D environments. For investors this matters because these platforms create new ways to sell products, deliver services, advertise, and improve operations—similar to moving from text-only websites to immersive storefronts and workspaces that can open fresh revenue and efficiency opportunities.

biomarkers medical

"The research aims to identify clinically relevant biomarkers that may help predict"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

tumor microenvironment medical

"understanding of tumor biology and the tumor microenvironment, including features"

The tumor microenvironment is the immediate area surrounding a cancer cell, made up of nearby cells, blood vessels, and support structures that influence how the cancer grows and spreads. It functions like a bustling neighborhood that can either help or hinder the tumor’s development. For investors, understanding changes in this environment can signal the effectiveness of treatments and potential shifts in a cancer-related market.

single-cell transcriptomic profiling medical

"to integrate single-cell transcriptomic profiling, spatial gene expression and protein"

Single-cell transcriptomic profiling is a laboratory method that measures which genes are active inside individual cells rather than averaging many cells together. Like listening to each person's voice in a crowded room, it reveals distinct cell types, rare cells, and how cells respond to treatment. For investors, this detail can speed discovery of drug targets, biomarkers and diagnostics, reduce clinical risk, and help companies pursue more precise, potentially higher-value therapies.

spatial gene expression medical

"integrate single-cell transcriptomic profiling, spatial gene expression and protein"

Spatial gene expression maps which genes are active and exactly where they are active within a tissue, like a city map showing which buildings have their lights on. For investors, this matters because those location patterns help companies identify drug targets, biomarkers and patient groups, improve diagnostics and guide more precise therapies—information that can lower R&D risk, sharpen clinical trials and increase the chances of commercial success.

antibody-drug conjugates medical

"patients treated with antibody-drug conjugates and immunotherapy and to integrate"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Collaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platforms

PLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer.

This collaboration is part of 10x's broader efforts to partner with leading research institutions to generate the evidence needed to support the future development of diagnostic applications across oncology and other disease areas.

Through this multi-year collaboration, the study intends to initially examine tumor samples from patients with advanced bladder cancer undergoing emerging therapeutic regimens using 10x's Flex Apex and Xenium platforms, with the goal of expanding to the recently announced Atera platform. The research aims to identify clinically relevant biomarkers that may help predict bladder cancer patient response to treatment and support future diagnostic development across tumor types.

Bladder cancer remains a complex and heterogeneous disease, with variable responses to therapies such as antibody-drug conjugates and immunotherapies. A major challenge in oncology is determining which therapies are most likely to benefit individual patients. By integrating single cell and spatial analysis, the research aims to generate a more comprehensive understanding of tumor biology and the tumor microenvironment, including features that may influence treatment response and resistance, which remain difficult to characterize using conventional approaches.

"We look forward to collaborating with 10x Genomics on this promising work. This collaboration has the potential to shed new light into the mechanisms underlying therapeutic response in a number of major cancer types," said Timothy Chan, MD, PhD, Chair, Department of Cancer Sciences, Cleveland Clinic.

The study is expected to include tumor samples from patients treated with antibody-drug conjugates and immunotherapy and to integrate single-cell transcriptomic profiling, spatial gene expression and protein measurements. Researchers plan to analyze tumor microenvironment composition, immune cell infiltration and expression of therapeutic targets to better understand mechanisms of response and resistance.

"One of the central challenges in oncology today is understanding why patients respond differently to the same therapy," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "There is a clear need for biomarkers that can guide treatment decisions, and we believe Flex Apex, Xenium and now Atera are uniquely suited to uncover them. These insights will be critical to enabling a new generation of diagnostic approaches in oncology."

The collaboration is expected to generate a comprehensive, multimodal dataset linking single cell and spatial insights with clinical outcomes, helping to advance the scientific understanding of treatment response in bladder cancer and support future diagnostic applications.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated research solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X, Facebook, Bluesky or YouTube.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-and-cleveland-clinic-collaborate-to-advance-research-in-diagnostic-applications-of-single-cell-and-spatial-technologies-in-patients-with-bladder-cancer-302802437.html

SOURCE 10x Genomics, Inc.

FAQ

What is the 10x Genomics (NASDAQ: TXG) and Cleveland Clinic bladder cancer collaboration announced on June 17, 2026?

10x Genomics and Cleveland Clinic launched a multi-year research collaboration focused on diagnostic applications in bladder cancer. According to 10x Genomics, the project will analyze advanced bladder cancer tumor samples to uncover biomarkers linked to treatment response and resistance using single cell and spatial technologies.

What is the main goal of the 10x Genomics (TXG) bladder cancer study with Cleveland Clinic?

The main goal is to identify biomarkers that may predict how bladder cancer patients respond to antibody-drug conjugates and immunotherapies. According to 10x Genomics, these biomarkers could support future diagnostic development across tumor types and help guide personalized treatment decisions in oncology.

Which 10x Genomics platforms are used in the Cleveland Clinic bladder cancer research collaboration?

The collaboration initially uses 10x Genomics’ Flex Apex and Xenium platforms, with plans to expand to Atera. According to 10x Genomics, these platforms enable integrated single cell transcriptomic profiling, spatial gene expression and protein measurements to better characterize tumor biology and the tumor microenvironment.

How will the 10x Genomics (TXG) and Cleveland Clinic study improve understanding of treatment response in bladder cancer?

The study will link single cell and spatial data with clinical outcomes from patients treated with ADCs and immunotherapies. According to 10x Genomics, researchers will assess tumor microenvironment composition, immune cell infiltration and therapeutic target expression to clarify mechanisms of response and resistance.

Does the 10x Genomics and Cleveland Clinic collaboration focus only on bladder cancer diagnostics?

The current study centers on advanced bladder cancer, but insights may extend beyond this disease. According to 10x Genomics, the collaboration is part of broader efforts to generate evidence supporting future diagnostic applications across oncology and potentially other disease areas.

What type of dataset will the 10x Genomics (TXG) and Cleveland Clinic bladder cancer project generate for researchers?

The project is expected to create a comprehensive, multimodal dataset linking single cell and spatial profiles with patient outcomes. According to 10x Genomics, this dataset should advance scientific understanding of treatment response in bladder cancer and inform development of new diagnostic approaches.